Lishui Central Hospital

The RBMS1–SLC7A11 axis regulates ferroptosis susceptibility and lenvatinib sensitivity in hepatocellular carcinoma

Hepatocellular carcinoma remains a leading cause of cancer-related mortality worldwide. Although lenvatinib is widely deployed as a frontline systemic therapy for advanced disease, its clinical utility is frequently subverted by primary or adaptive non-responsiveness. Evasion of...

Impact of imperatorin and isoimperatorin on the pharmacokinetics of abemaciclib both in vivo and in vitro

<title>Abstract</title> Abemaciclib is used for the treatment of breast cancer (BC) in clinics. The combination of abemaciclib and imperatorin or isoimperatorin has been studied <italic>in vitro</italic> and <italic>in vivo</italic> to explore the pharmacokinetics of Chinese herb...

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Mefatinib, a novel second-generation epidermal growth factor (EGFR) tyrosine kinase inhibitor that has shown promising antitumor activity in targeting non-small cell lung cancer (NSCLC) with common and uncommon EGFR- activating mutations. In this phase III, randomized, double-bli...

The diagnostic role of SARS-CoV-2 in routine respiratory testing after policy adjustment: a real-world laboratory study integrating longitudinal PCR and respiratory pathogen testing workflow data

Since COVID-19 entered long-term management, SARS-CoV-2 has become increasingly integrated into routine respiratory diagnostics. However, longitudinal laboratory trends and its relative position within multiplex respiratory pathogen testing remain incompletely described in real-w...